Jazz Pharmaceuticals (JAZZ) Financials

$102.91 +1.16 (+1.14%)

Closing price 04/15/2025 04:00 PM Eastern

Extended Trading

$100.68 -2.23 (-2.17%)

As of 04/15/2025 07:29 PM Eastern

Annual Income Statements for Jazz Pharmaceuticals

This table shows Jazz Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	330	397	488	447	523	239	-330	-224	415	560
Consolidated Net Income / (Loss)	330	397	488	447	523	239	-330	-224	415	560
Net Income / (Loss) Continuing Operations	330	397	488	447	523	239	-330	-224	415	560
Total Pre-Tax Income	436	532	441	529	454	275	-113	-373	298	470
Total Operating Income	508	592	529	615	532	378	170	-66	579	717
Total Gross Profit	1,222	1,383	1,509	1,769	2,034	2,215	2,653	3,119	3,399	3,623
Total Revenue	1,325	1,488	1,619	1,891	2,162	2,364	3,094	3,659	3,834	4,069
Operating Revenue	1,325	1,488	1,619	1,891	2,162	2,364	3,094	3,659	3,834	4,069
Total Cost of Revenue	103	105	110	122	128	149	441	541	436	446
Operating Cost of Revenue	103	105	110	122	128	149	441	541	436	446
Total Operating Expenses	714	791	980	1,155	1,501	1,837	2,483	3,184	2,820	2,907
Selling, General & Admin Expense	449	503	544	684	737	854	1,452	1,417	1,343	1,385
Research & Development Expense	135	186	283	227	410	587	506	1,035	869	894
Amortization Expense	98	102	152	201	355	260	526	599	608	627
Impairment Charge	32	0.00	0.00	43	0.00	136	0.00	134	0.00	0.00
Total Other Income / (Expense), net	-72	-59	-88	-85	-78	-103	-283	-307	-281	-246
Interest & Investment Income	-57	-62	-78	-79	-72	-100	-279	-288	-289	-238
Other Income / (Expense), net	1.45	3.37	-9.97	-6.88	-5.81	-3.27	-4.35	-19	8.79	-8.18
Income Tax Expense	106	135	-48	80	-73	34	216	-159	-120	-91
Other Gains / (Losses), net	0.00	-0.38	-1.01	-2.20	-4.09	-2.96	-0.71	-9.92	-3.01	-1.66
Basic Earnings per Share	$5.38	$6.56	$8.13	$7.45	$9.22	$4.28	($5.52)	($3.58)	$6.55	$9.06
Weighted Average Basic Shares Outstanding	61.23M	60.50M	60.02M	59.98M	56.75M	55.71M	59.69M	62.54M	63.29M	61.84M
Diluted Earnings per Share	$5.23	$6.41	$7.96	$7.30	$9.09	$4.22	($5.52)	($3.58)	$6.10	$8.65
Weighted Average Diluted Shares Outstanding	63.04M	61.87M	61.32M	61.22M	57.55M	56.52M	59.69M	62.54M	72.07M	66.01M
Weighted Average Basic & Diluted Shares Outstanding	61.30M	60.50M	60M	60M	56.13M	56.33M	61.74M	63.33M	62.35M	60.73M

This table shows Jazz Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-20	-241	69	104	147	94	-15	169	215	191
Consolidated Net Income / (Loss)	-20	-241	69	104	147	94	-15	169	215	191
Net Income / (Loss) Continuing Operations	-20	-241	69	104	147	94	-15	169	215	191
Total Pre-Tax Income	-60	-340	55	82	100	62	-1.60	138	201	133
Total Operating Income	25	-263	126	158	172	122	66	199	260	191
Total Gross Profit	807	805	764	860	870	905	806	914	943	959
Total Revenue	941	972	893	957	972	1,012	902	1,024	1,055	1,088
Operating Revenue	941	972	893	957	972	1,012	902	1,024	1,055	1,088
Total Cost of Revenue	134	167	129	98	102	107	95	110	112	129
Operating Cost of Revenue	134	167	129	98	102	107	95	110	112	129
Total Operating Expenses	782	1,068	638	702	698	782	740	714	683	769
Selling, General & Admin Expense	358	383	298	341	308	396	352	339	326	369
Research & Development Expense	149	548	190	209	234	235	233	221	200	241
Amortization Expense	141	137	150	152	155	152	156	155	157	159
Total Other Income / (Expense), net	-85	-77	-71	-76	-73	-61	-68	-62	-59	-58
Interest & Investment Income	-80	-74	-74	-73	-71	-70	-66	-62	-59	-51
Other Income / (Expense), net	-4.65	-2.48	3.19	-2.38	-1.38	9.35	-1.69	0.51	-0.70	-6.30
Income Tax Expense	-43	-100	-15	-24	-47	-33	12	-31	-15	-58
Other Gains / (Losses), net	-2.55	-0.77	-1.01	-1.67	0.13	-0.46	-1.35	-0.01	-0.29	-0.02
Basic Earnings per Share	($0.31)	($3.86)	$1.09	$1.63	$2.33	$1.50	($0.23)	$2.68	$3.50	$3.11
Weighted Average Basic Shares Outstanding	62.79M	62.54M	63.49M	63.99M	63.11M	63.29M	62.54M	62.88M	61.41M	61.84M
Diluted Earnings per Share	($0.31)	($3.85)	$1.04	$1.52	$2.14	$1.40	($0.23)	$2.49	$3.42	$2.97
Weighted Average Diluted Shares Outstanding	62.79M	62.54M	73.77M	73.54M	71.29M	72.07M	62.54M	69.63M	63.17M	66.01M
Weighted Average Basic & Diluted Shares Outstanding	62.97M	63.33M	64.00M	63.13M	62.96M	62.35M	63.04M	61.75M	60.45M	60.73M

This table details how cash moves in and out of Jazz Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	305	-623	20	-75	328	420	-466	290	625	907
Net Cash From Operating Activities	532	592	693	799	776	900	779	1,272	1,092	1,396
Net Cash From Continuing Operating Activities	532	592	693	799	776	900	779	1,272	1,092	1,396
Net Income / (Loss) Continuing Operations	330	397	488	447	523	239	-330	-224	415	560
Consolidated Net Income / (Loss)	330	397	488	447	523	239	-330	-224	415	560
Depreciation Expense	9.89	12	13	15	15	19	27	30	30	33
Amortization Expense	121	124	182	245	355	260	526	599	608	627
Non-Cash Adjustments To Reconcile Net Income	139	122	209	159	288	618	550	1,164	518	478
Changes in Operating Assets and Liabilities, net	-67	-62	-199	-68	-405	-235	5.66	-297	-480	-302
Net Cash From Investing Activities	-2.26	-1,751	-269	-394	-155	-1,008	-5,212	-446	-163	-508
Net Cash From Continuing Investing Activities	-2.26	-1,751	-269	-394	-155	-1,008	-5,212	-446	-163	-508
Purchase of Property, Plant & Equipment	-36	-9.69	-29	-20	-40	-15	-28	-29	-24	-38
Acquisitions	0.00	-1,676	-85	-111	-197	-364	-6,253	-469	-19	-10
Purchase of Investments	0.00	-132	-385	-1,166	-917	-2,398	-27	-61	-390	-1,305
Divestitures	34	-	-	-	-	14	0.00	53	0.00	0.00
Sale and/or Maturity of Investments	0.00	67	230	855	985	1,755	1,095	60	270	845
Net Cash From Financing Activities	-214	541	-409	-479	-294	528	3,971	-529	-305	21
Net Cash From Continuing Financing Activities	-214	541	-409	-479	-294	528	3,971	-529	-305	21
Repayment of Debt	-1,066	-178	-886	-32	-33	-890	-1,321	-582	-31	-612
Repurchase of Common Equity	-62	-278	-99	-524	-301	-147	0.00	-0.05	-270	-311
Issuance of Debt	899	995	559	0.00	0.00	1,481	5,191	0.00	0.00	981
Issuance of Common Equity	41	24	32	93	58	100	135	98	46	21
Other Financing Activities, net	-26	-21	-15	-17	-17	-17	-36	-45	-51	-58
Other Net Changes in Cash	-	-	5.05	-	-	-	-3.21	-6.22	-	-1.68
Cash Interest Paid	40	40	45	43	43	42	138	271	333	315
Cash Income Taxes Paid	146	160	174	164	184	227	271	95	178	115

This table details how cash moves in and out of Jazz Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	128	42	286	114	53	171	-63	-88	862	195
Net Cash From Operating Activities	418	342	321	297	307	167	267	331	399	399
Net Cash From Continuing Operating Activities	418	342	321	297	307	167	267	331	399	399
Net Income / (Loss) Continuing Operations	-20	-241	69	104	147	94	-15	169	215	191
Consolidated Net Income / (Loss)	-20	-241	69	104	147	94	-15	169	215	191
Depreciation Expense	7.59	7.34	7.57	7.52	7.68	7.65	7.65	7.81	7.78	9.51
Amortization Expense	141	137	150	152	155	152	156	155	157	159
Non-Cash Adjustments To Reconcile Net Income	287	529	146	136	104	131	132	105	113	128
Changes in Operating Assets and Liabilities, net	1.42	-91	-52	-104	-106	-217	-14	-105	-94	-89
Net Cash From Investing Activities	4.60	-324	-4.82	-86	-174	102	-272	-257	214	-193
Net Cash From Continuing Investing Activities	4.60	-324	-4.82	-86	-174	102	-272	-257	214	-193
Purchase of Property, Plant & Equipment	4.90	-9.38	-3.82	-5.74	-4.30	-10	-6.90	-7.09	-11	-13
Purchase of Investments	-0.30	-	0.00	-80	-190	-120	-375	-330	-130	-470
Sale and/or Maturity of Investments	-	60	0.00	-	20	250	120	80	355	290
Net Cash From Financing Activities	-289	20	-30	-97	-78	-100	-57	-161	246	-8.28
Net Cash From Continuing Financing Activities	-289	20	-30	-97	-78	-100	-57	-161	246	-8.28
Repayment of Debt	-308	-7.75	-7.75	-7.75	-7.75	-7.75	-7.75	-7.75	-583	-13
Issuance of Common Equity	21	30	21	11	5.51	8.85	0.49	11	0.02	9.20
Other Financing Activities, net	-2.57	-2.81	-43	-4.19	-1.88	-1.61	-49	-2.85	-1.61	-4.01
Other Net Changes in Cash	-	4.94	-	-	-1.02	-	-1.70	-0.76	3.07	-2.29

This table presents Jazz Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	3,333	4,800	5,124	5,203	5,539	6,536	12,299	10,835	11,393	12,012
Total Current Assets	1,258	748	968	1,234	1,630	2,840	2,611	2,606	3,435	4,629
Cash & Equivalents	989	366	386	310	637	1,058	591	881	1,506	2,413
Short-Term Investments	0.00	60	215	515	440	1,075	-	0.00	120	580
Accounts Receivable	210	234	224	264	356	396	563	651	706	717
Inventories, net	19	34	43	53	79	95	1,073	714	597	480
Prepaid Expenses	21	25	23	25	39	62	131	92	185	177
Other Current Assets	19	29	77	68	79	152	252	267	321	262
Plant, Property, & Equipment, net	86	107	170	200	132	128	257	228	170	173
Total Noncurrent Assets	1,989	3,945	3,985	3,769	3,777	3,568	9,430	8,001	7,788	7,210
Goodwill	657	894	948	928	920	958	1,828	1,693	1,753	1,716
Intangible Assets	1,186	3,012	2,979	2,731	2,441	2,195	7,152	5,794	5,418	4,756
Noncurrent Deferred & Refundable Income Taxes	130	15	35	58	221	255	311	376	478	560
Other Noncurrent Operating Assets	9.27	14	16	43	187	155	127	128	133	168
Other Noncurrent Nonoperating Assets	7.21	9.74	7.67	9.59	7.43	5.24	12	9.25	6.48	9.49
Total Liabilities & Shareholders' Equity	3,333	4,800	5,124	5,203	5,539	6,536	12,299	10,835	11,393	12,012
Total Liabilities	1,734	2,923	2,411	2,446	2,428	2,876	8,333	7,750	7,656	7,919
Total Current Liabilities	227	257	294	345	364	654	809	933	1,537	1,039
Short-Term Debt	38	36	41	33	33	246	31	31	605	31
Accounts Payable	22	22	24	41	46	27	100	91	103	78
Accrued Expenses	164	193	199	265	270	353	666	803	794	911
Current Deferred & Payable Income Tax Liabilities	1.81	4.51	22	1.20	11	25	9.61	7.72	35	19
Total Noncurrent Liabilities	1,507	2,665	2,117	2,101	2,063	2,222	7,524	6,816	6,120	6,880
Long-Term Debt	1,151	1,994	1,540	1,563	1,574	1,849	6,019	5,693	5,108	6,078
Noncurrent Deferred & Payable Income Tax Liabilities	283	557	383	309	224	130	1,301	944	848	677
Other Noncurrent Operating Liabilities	69	113	177	219	261	241	204	179	164	126
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,599	1,877	2,713	2,757	3,111	3,660	3,965	3,086	3,737	4,094
Total Preferred & Common Equity	1,599	1,877	2,713	2,757	3,111	3,660	3,965	3,086	3,737	4,094
Total Common Equity	1,599	1,877	2,713	2,757	3,111	3,660	3,965	3,086	3,737	4,094
Common Stock	1,563	1,665	1,935	2,114	2,266	2,634	3,535	3,477	3,700	3,914
Retained Earnings	303	529	918	841	1,068	1,160	830	734	879	1,127
Accumulated Other Comprehensive Income / (Loss)	-267	-317	-141	-198	-223	-134	-400	-1,126	-842	-948
Other Equity Adjustments	0.53	0.53	0.53	0.53	0.53	0.53	0.53	0.53	0.53	0.53

This table presents Jazz Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	10,385	11,047	11,261	11,204	11,327	11,362	12,256
Total Current Assets	2,572	2,785	3,010	3,246	3,540	3,682	4,390
Cash & Equivalents	839	1,168	1,282	1,336	1,443	1,356	2,218
Short-Term Investments	60	-	80	250	375	625	400
Accounts Receivable	601	624	610	628	707	698	724
Inventories, net	728	675	657	612	577	543	539
Prepaid Expenses	93	73	107	110	123	134	155
Other Current Assets	250	245	272	310	315	326	354
Plant, Property, & Equipment, net	216	228	229	222	166	169	176
Total Noncurrent Assets	7,597	8,035	8,021	7,736	7,621	7,511	7,689
Goodwill	1,593	1,723	1,743	1,705	1,739	1,736	1,805
Intangible Assets	5,570	5,764	5,706	5,418	5,235	5,079	5,144
Noncurrent Deferred & Refundable Income Taxes	315	399	430	464	508	545	583
Other Noncurrent Operating Assets	109	140	135	141	132	145	152
Other Noncurrent Nonoperating Assets	9.95	8.56	7.87	7.17	5.78	5.74	4.40
Total Liabilities & Shareholders' Equity	10,385	11,047	11,261	11,204	11,327	11,362	12,256
Total Liabilities	7,639	7,712	7,735	7,715	7,631	7,599	8,085
Total Current Liabilities	813	909	945	1,573	1,562	1,556	1,030
Short-Term Debt	31	31	31	605	605	606	31
Accounts Payable	102	125	98	110	81	97	85
Accrued Expenses	668	712	748	770	827	801	859
Current Deferred & Payable Income Tax Liabilities	10	40	68	89	49	52	55
Total Noncurrent Liabilities	6,827	6,803	6,790	6,141	6,068	6,043	7,055
Long-Term Debt	5,696	5,690	5,687	5,111	5,105	5,101	6,081
Noncurrent Deferred & Payable Income Tax Liabilities	934	932	911	841	810	775	792
Other Noncurrent Operating Liabilities	197	181	192	189	154	167	182
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,745	3,335	3,526	3,489	3,696	3,763	4,171
Total Preferred & Common Equity	2,745	3,335	3,526	3,489	3,696	3,763	4,171
Total Common Equity	2,745	3,335	3,526	3,489	3,696	3,763	4,171
Common Stock	3,388	3,512	3,580	3,640	3,714	3,779	3,838
Retained Earnings	974	803	812	884	864	871	936
Accumulated Other Comprehensive Income / (Loss)	-1,618	-980	-867	-1,035	-882	-888	-603
Other Equity Adjustments	0.53	0.53	0.53	0.53	0.53	0.53	0.53

This table displays calculated financial ratios and metrics derived from Jazz Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	12.95%	12.32%	8.79%	16.82%	14.32%	9.34%	30.91%	18.26%	4.78%	6.12%
EBITDA Growth	82.12%	14.13%	-2.31%	21.65%	3.23%	-27.17%	10.01%	-24.15%	125.00%	11.62%
EBIT Growth	149.51%	16.75%	-12.80%	17.17%	-13.39%	-28.82%	-55.73%	-150.95%	794.76%	20.61%
NOPAT Growth	419.30%	14.89%	32.78%	-10.98%	18.47%	-46.29%	-64.10%	-138.48%	1,869.04%	5.48%
Net Income Growth	474.84%	20.42%	22.94%	-8.35%	17.06%	-54.41%	-238.16%	32.03%	285.14%	35.02%
EPS Growth	462.37%	22.56%	24.18%	-8.29%	24.52%	-53.58%	-230.81%	35.14%	270.39%	41.80%
Operating Cash Flow Growth	30.50%	11.36%	17.00%	15.27%	-2.82%	15.87%	-13.47%	63.39%	-14.15%	27.83%
Free Cash Flow Firm Growth	182.64%	-310.02%	130.02%	84.87%	-26.66%	-30.81%	-1,726.79%	125.48%	-36.84%	61.23%
Invested Capital Growth	-10.30%	93.81%	6.17%	-4.50%	3.23%	-0.46%	160.24%	-15.86%	-1.29%	-7.89%
Revenue Q/Q Growth	0.97%	3.89%	2.52%	2.16%	5.12%	3.67%	8.08%	2.10%	1.05%	1.91%
EBITDA Q/Q Growth	-4.69%	9.83%	0.27%	4.48%	-4.53%	6.79%	-4.73%	-37.68%	50.65%	4.73%
EBIT Q/Q Growth	-4.35%	11.57%	-5.48%	7.61%	-19.10%	43.36%	-43.67%	-137.56%	209.71%	8.02%
NOPAT Q/Q Growth	0.08%	9.01%	34.42%	-15.40%	-10.94%	16.82%	119.13%	-126.50%	501.57%	13.12%
Net Income Q/Q Growth	0.35%	9.35%	31.03%	-13.99%	-14.04%	33.16%	-104.89%	-1,099.02%	418.84%	20.93%
EPS Q/Q Growth	-1.51%	9.95%	31.35%	-13.71%	-13.01%	33.54%	-117.32%	-867.57%	617.65%	22.18%
Operating Cash Flow Q/Q Growth	-2.66%	11.47%	3.57%	1.72%	-14.37%	12.29%	-1.08%	14.82%	-13.79%	19.85%
Free Cash Flow Firm Q/Q Growth	-7.25%	-2.89%	19.66%	4.49%	-23.69%	8.19%	14.17%	-32.49%	964.67%	108.02%
Invested Capital Q/Q Growth	-3.41%	0.23%	2.70%	-0.78%	1.48%	2.10%	-1.27%	4.72%	2.70%	-6.01%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	92.26%	92.92%	93.19%	93.57%	94.08%	93.70%	85.76%	85.23%	88.64%	89.05%
EBITDA Margin	48.34%	49.12%	44.11%	45.94%	41.48%	27.63%	23.22%	14.89%	31.98%	33.63%
Operating Margin	38.36%	39.76%	32.67%	32.52%	24.63%	16.00%	5.50%	-1.79%	15.09%	17.61%
EBIT Margin	38.47%	39.99%	32.06%	32.15%	24.36%	15.86%	5.36%	-2.31%	15.32%	17.41%
Profit (Net Income) Margin	24.87%	26.67%	30.14%	23.64%	24.21%	10.10%	-10.65%	-6.12%	10.82%	13.77%
Tax Burden Percent	75.59%	74.53%	110.59%	84.44%	115.20%	86.74%	292.16%	60.10%	139.24%	119.09%
Interest Burden Percent	85.53%	89.48%	85.01%	87.09%	86.28%	73.40%	-68.00%	440.95%	50.72%	66.39%
Effective Tax Rate	24.41%	25.40%	-10.82%	15.14%	-16.10%	12.18%	0.00%	0.00%	-40.25%	-19.44%
Return on Invested Capital (ROIC)	20.28%	16.78%	16.38%	14.48%	17.28%	9.16%	1.83%	-0.53%	10.31%	11.40%
ROIC Less NNEP Spread (ROIC-NNEP)	6.92%	11.79%	8.72%	5.88%	2.53%	-29.81%	-14.78%	-4.00%	1.41%	3.17%
Return on Net Nonoperating Assets (RNNOA)	1.91%	6.06%	4.88%	1.86%	0.55%	-2.11%	-10.48%	-5.83%	1.85%	2.91%
Return on Equity (ROE)	22.19%	22.83%	21.26%	16.35%	17.84%	7.05%	-8.65%	-6.36%	12.16%	14.31%
Cash Return on Invested Capital (CROIC)	31.14%	-47.08%	10.39%	19.09%	14.10%	9.62%	-87.13%	16.69%	11.61%	19.62%
Operating Return on Assets (OROA)	15.28%	14.63%	10.46%	11.77%	9.80%	6.21%	1.76%	-0.73%	5.28%	6.05%
Return on Assets (ROA)	9.88%	9.76%	9.83%	8.66%	9.74%	3.95%	-3.50%	-1.94%	3.73%	4.79%
Return on Common Equity (ROCE)	22.19%	22.83%	21.26%	16.35%	17.84%	7.05%	-8.65%	-6.36%	12.16%	14.31%
Return on Equity Simple (ROE_SIMPLE)	20.61%	21.14%	17.98%	16.21%	16.82%	6.52%	-8.31%	-7.26%	11.10%	13.68%
Net Operating Profit after Tax (NOPAT)	384	441	586	522	618	332	119	-46	811	856
NOPAT Margin	29.00%	29.66%	36.21%	27.59%	28.59%	14.05%	3.85%	-1.25%	21.16%	21.04%
Net Nonoperating Expense Percent (NNEP)	13.36%	4.99%	7.66%	8.61%	14.75%	38.97%	16.61%	3.47%	8.90%	8.23%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-0.52%	8.59%	8.39%
Cost of Revenue to Revenue	7.74%	7.08%	6.81%	6.43%	5.92%	6.30%	14.24%	14.77%	11.36%	10.95%
SG&A Expenses to Revenue	33.90%	33.80%	33.62%	36.15%	34.09%	36.14%	46.92%	38.72%	35.03%	34.05%
R&D to Revenue	10.21%	12.50%	17.51%	11.98%	18.95%	24.82%	16.34%	28.27%	22.66%	21.97%
Operating Expenses to Revenue	53.90%	53.16%	60.52%	61.06%	69.46%	77.70%	80.25%	87.02%	73.55%	71.43%
Earnings before Interest and Taxes (EBIT)	510	595	519	608	527	375	166	-85	587	708
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	640	731	714	869	897	653	718	545	1,226	1,369
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.41	3.48	2.98	2.71	2.71	2.51	1.98	3.25	2.07	1.82
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	18.16	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	6.52	4.39	4.99	3.95	3.91	3.89	2.53	2.74	2.02	1.83
Price to Earnings (P/E)	26.23	16.46	16.55	16.72	16.14	38.54	0.00	0.00	18.67	13.29
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.81%	6.08%	6.04%	5.98%	6.20%	2.59%	0.00%	0.00%	5.36%	7.52%
Enterprise Value to Invested Capital (EV/IC)	4.94	2.34	2.46	2.34	2.47	2.53	1.41	1.88	1.51	1.47
Enterprise Value to Revenue (EV/Rev)	6.68	5.47	5.59	4.36	4.15	3.87	4.30	4.06	3.09	2.60
Enterprise Value to EBITDA (EV/EBITDA)	13.81	11.13	12.68	9.50	10.01	14.02	18.50	27.30	9.65	7.72
Enterprise Value to EBIT (EV/EBIT)	17.35	13.67	17.45	13.57	17.04	24.43	80.09	0.00	20.14	14.91
Enterprise Value to NOPAT (EV/NOPAT)	23.02	18.43	15.45	15.81	14.52	27.58	111.50	0.00	14.58	12.34
Enterprise Value to Operating Cash Flow (EV/OCF)	16.63	13.73	13.06	10.33	11.56	10.18	17.07	11.69	10.83	7.57
Enterprise Value to Free Cash Flow (EV/FCFF)	14.99	0.00	24.34	12.00	17.80	26.25	0.00	10.28	12.95	7.17
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.74	1.08	0.58	0.58	0.52	0.57	1.53	1.86	1.53	1.49
Long-Term Debt to Equity	0.72	1.06	0.57	0.57	0.51	0.51	1.52	1.85	1.37	1.48
Financial Leverage	0.28	0.51	0.56	0.32	0.22	0.07	0.71	1.46	1.31	0.92
Leverage Ratio	2.25	2.34	2.16	1.89	1.83	1.78	2.47	3.28	3.26	2.99
Compound Leverage Factor	1.92	2.09	1.84	1.64	1.58	1.31	-1.68	14.47	1.65	1.98
Debt to Total Capital	42.64%	51.95%	36.82%	36.67%	34.06%	36.40%	60.41%	64.97%	60.45%	59.87%
Short-Term Debt to Total Capital	1.35%	0.92%	0.95%	0.77%	0.71%	4.28%	0.31%	0.35%	6.40%	0.30%
Long-Term Debt to Total Capital	41.29%	51.03%	35.87%	35.90%	33.36%	32.12%	60.10%	64.62%	54.05%	59.57%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	57.36%	48.05%	63.18%	63.33%	65.94%	63.60%	39.59%	35.03%	39.55%	40.13%
Debt to EBITDA	1.86	2.78	2.21	1.84	1.79	3.21	8.42	10.50	4.66	4.46
Net Debt to EBITDA	0.31	2.19	1.37	0.89	0.59	-0.06	7.60	8.89	3.33	2.28
Long-Term Debt to EBITDA	1.80	2.73	2.16	1.80	1.76	2.83	8.38	10.45	4.17	4.44
Debt to NOPAT	3.09	4.60	2.70	3.06	2.60	6.31	50.76	-124.80	7.04	7.14
Net Debt to NOPAT	0.52	3.63	1.67	1.48	0.86	-0.11	45.79	-105.58	5.04	3.64
Long-Term Debt to NOPAT	3.00	4.52	2.63	3.00	2.55	5.57	50.50	-124.12	6.29	7.10
Altman Z-Score	4.39	2.34	3.07	3.01	3.34	3.12	1.13	1.37	1.42	1.59
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.55	2.91	3.29	3.57	4.47	4.34	3.23	2.79	2.24	4.46
Quick Ratio	5.29	2.56	2.81	3.15	3.93	3.87	1.43	1.64	1.52	3.57
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	590	-1,239	372	688	504	349	-5,676	1,446	914	1,473
Operating Cash Flow to CapEx	1,479.35%	6,115.32%	2,394.08%	0.00%	2,994.68%	5,996.05%	2,816.49%	4,379.18%	4,557.24%	3,666.69%
Free Cash Flow to Firm to Interest Expense	35.08	-1,941.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	31.64	928.51	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	29.50	913.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.40	0.37	0.33	0.37	0.40	0.39	0.33	0.32	0.35	0.35
Accounts Receivable Turnover	6.69	6.70	7.06	7.75	6.98	6.28	6.45	6.02	5.65	5.72
Inventory Turnover	4.14	3.94	2.85	2.53	1.94	1.71	0.75	0.61	0.66	0.83
Fixed Asset Turnover	18.41	15.41	11.66	10.21	13.03	18.22	16.08	15.09	19.28	23.72
Accounts Payable Turnover	4.37	4.77	4.71	3.74	2.96	4.10	6.93	5.66	4.50	4.94
Days Sales Outstanding (DSO)	54.56	54.45	51.68	47.10	52.33	58.10	56.61	60.59	64.60	63.80
Days Inventory Outstanding (DIO)	88.09	92.65	128.02	144.45	187.68	213.24	483.67	603.29	549.33	441.18
Days Payable Outstanding (DPO)	83.54	76.58	77.48	97.55	123.16	89.07	52.69	64.51	81.08	73.96
Cash Conversion Cycle (CCC)	59.11	70.52	102.22	93.99	116.85	182.28	487.59	599.37	532.86	431.03
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,791	3,471	3,685	3,520	3,633	3,617	9,412	7,919	7,817	7,200
Invested Capital Turnover	0.70	0.57	0.45	0.52	0.60	0.65	0.48	0.42	0.49	0.54
Increase / (Decrease) in Invested Capital	-206	1,680	214	-166	114	-17	5,795	-1,492	-102	-617
Enterprise Value (EV)	8,844	8,134	9,052	8,249	8,975	9,158	13,290	14,874	11,830	10,561
Market Capitalization	8,644	6,530	8,072	7,477	8,445	9,196	7,831	10,031	7,744	7,445
Book Value per Share	$26.00	$31.35	$45.26	$45.71	$54.99	$65.69	$64.51	$49.01	$59.36	$67.72
Tangible Book Value per Share	($3.97)	($33.87)	($20.24)	($14.95)	($4.42)	$9.09	($81.58)	($69.90)	($54.55)	($39.34)
Total Capital	2,787	3,907	4,294	4,354	4,718	5,755	10,015	8,810	9,450	10,202
Total Debt	1,188	2,030	1,581	1,596	1,607	2,095	6,050	5,724	5,713	6,109
Total Long-Term Debt	1,151	1,994	1,540	1,563	1,574	1,849	6,019	5,693	5,108	6,078
Net Debt	200	1,604	980	772	530	-38	5,458	4,843	4,087	3,116
Capital Expenditures (CapEx)	36	9.69	29	-28	26	15	28	29	24	38
Debt-free, Cash-free Net Working Capital (DFCFNWC)	80	101	114	97	222	299	1,242	822	877	629
Debt-free Net Working Capital (DFNWC)	1,069	527	715	922	1,299	2,432	1,833	1,704	2,504	3,621
Net Working Capital (NWC)	1,031	491	674	889	1,266	2,186	1,802	1,673	1,899	3,590
Net Nonoperating Expense (NNE)	55	45	98	75	95	93	449	178	397	296
Net Nonoperating Obligations (NNO)	192	1,594	972	762	522	-43	5,446	4,834	4,080	3,106
Total Depreciation and Amortization (D&A)	131	136	195	261	370	278	552	629	639	660
Debt-free, Cash-free Net Working Capital to Revenue	6.03%	6.77%	7.04%	5.14%	10.26%	12.67%	40.13%	22.48%	22.88%	15.45%
Debt-free Net Working Capital to Revenue	80.66%	35.40%	44.17%	48.75%	60.10%	102.90%	59.24%	46.56%	65.30%	89.00%
Net Working Capital to Revenue	77.82%	32.98%	41.66%	46.99%	58.55%	92.48%	58.24%	45.72%	49.52%	88.24%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$5.38	$6.56	$8.13	$7.45	$9.22	$4.28	($5.52)	($3.58)	$6.55	$9.06
Adjusted Weighted Average Basic Shares Outstanding	61.23M	60.50M	60.02M	59.98M	56.75M	55.71M	59.69M	62.54M	63.29M	61.84M
Adjusted Diluted Earnings per Share	$5.23	$6.41	$7.96	$7.30	$9.09	$4.22	($5.52)	($3.58)	$6.10	$8.65
Adjusted Weighted Average Diluted Shares Outstanding	63.04M	61.87M	61.32M	61.22M	57.55M	56.52M	59.69M	62.54M	72.07M	66.01M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	61.18M	59.74M	59.80M	57.06M	56.13M	56.33M	61.74M	63.33M	62.35M	60.73M
Normalized Net Operating Profit after Tax (NOPAT)	408	441	370	558	373	452	119	48	405	502
Normalized NOPAT Margin	30.80%	29.66%	22.87%	29.52%	17.24%	19.11%	3.85%	1.30%	10.56%	12.33%
Pre Tax Income Margin	32.91%	35.78%	27.25%	28.00%	21.02%	11.64%	-3.65%	-10.19%	7.77%	11.56%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	30.31	932.64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	22.85	691.82	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	28.17	917.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	20.71	676.63	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	18.68%	70.13%	20.25%	117.13%	57.60%	61.41%	0.00%	-0.02%	65.03%	55.60%

This table displays calculated financial ratios and metrics derived from Jazz Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	12.23%	8.41%	9.72%	2.62%	3.35%	4.10%	1.03%	6.95%	8.52%	7.53%
EBITDA Growth	-12.61%	-158.13%	11.64%	30.96%	97.45%	340.27%	-20.48%	15.30%	27.33%	21.25%
EBIT Growth	-21.85%	-707.45%	67.83%	84.38%	750.23%	149.59%	-50.09%	28.79%	51.75%	39.91%
NOPAT Growth	-12.71%	-633.39%	101.06%	35.32%	1,365.97%	202.17%	-71.23%	19.19%	9.81%	45.29%
Net Income Growth	62.81%	-580.95%	4,114.94%	201.28%	847.25%	139.11%	-121.06%	61.40%	46.48%	102.98%
EPS Growth	63.95%	-501.56%	3,366.67%	176.36%	790.32%	136.36%	-122.12%	63.82%	59.81%	112.14%
Operating Cash Flow Growth	52.52%	92.38%	53.46%	-2.07%	-26.51%	-51.07%	-16.68%	11.65%	29.80%	138.19%
Free Cash Flow Firm Growth	133.28%	122.71%	124.03%	-53.98%	-89.68%	-77.78%	-74.05%	-17.78%	12.41%	206.58%
Invested Capital Growth	-20.66%	-15.86%	-12.83%	-6.71%	0.65%	-1.29%	-3.76%	-4.96%	0.64%	-7.89%
Revenue Q/Q Growth	0.83%	3.35%	-8.16%	7.22%	1.55%	4.09%	-10.87%	13.51%	3.04%	3.15%
EBITDA Q/Q Growth	-29.73%	-171.70%	336.60%	9.85%	5.95%	-12.75%	-21.70%	59.28%	17.01%	-16.92%
EBIT Q/Q Growth	-76.11%	-1,421.81%	148.61%	20.12%	10.15%	-22.90%	-51.07%	209.93%	29.79%	-28.91%
NOPAT Q/Q Growth	-88.53%	-1,163.63%	187.39%	26.94%	24.25%	-25.87%	-75.40%	425.99%	14.47%	-1.91%
Net Income Q/Q Growth	-156.68%	-1,125.18%	128.84%	50.44%	40.58%	-35.87%	-115.53%	1,253.15%	27.58%	-11.13%
EPS Q/Q Growth	-156.36%	-1,141.94%	127.01%	46.15%	40.79%	-34.58%	-116.43%	1,182.61%	37.35%	-13.16%
Operating Cash Flow Q/Q Growth	37.93%	-18.19%	-6.22%	-7.47%	3.51%	-45.53%	59.69%	24.00%	20.34%	-0.04%
Free Cash Flow Firm Q/Q Growth	18.56%	-34.17%	1.01%	-41.62%	-73.41%	41.71%	17.98%	84.97%	-63.65%	286.50%
Invested Capital Q/Q Growth	-10.39%	4.72%	-0.51%	-0.08%	-3.32%	2.70%	-3.00%	-1.32%	2.37%	-6.01%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	85.79%	82.78%	85.59%	89.81%	89.49%	89.40%	89.41%	89.27%	89.42%	88.17%
EBITDA Margin	17.96%	-12.46%	32.10%	32.89%	34.31%	28.76%	25.27%	35.45%	40.26%	32.43%
Operating Margin	2.63%	-27.09%	14.12%	16.47%	17.73%	12.11%	7.34%	19.48%	24.67%	17.53%
EBIT Margin	2.14%	-27.35%	14.48%	16.22%	17.59%	13.03%	7.15%	19.53%	24.60%	16.95%
Profit (Net Income) Margin	-2.09%	-24.76%	7.78%	10.91%	15.10%	9.30%	-1.62%	16.46%	20.39%	17.56%
Tax Burden Percent	32.68%	70.80%	125.99%	127.70%	147.53%	153.03%	912.48%	122.22%	107.10%	143.46%
Interest Burden Percent	-298.95%	127.88%	42.63%	52.68%	58.19%	46.66%	-2.48%	68.98%	77.38%	72.22%
Effective Tax Rate	0.00%	0.00%	-27.81%	-29.74%	-47.40%	-53.78%	0.00%	-22.22%	-7.24%	-43.47%
Return on Invested Capital (ROIC)	0.77%	-8.01%	7.98%	9.86%	13.07%	9.07%	2.55%	12.12%	13.83%	13.63%
ROIC Less NNEP Spread (ROIC-NNEP)	0.06%	-9.11%	6.14%	7.77%	10.67%	6.96%	1.11%	10.26%	12.15%	11.33%
Return on Net Nonoperating Assets (RNNOA)	0.10%	-13.28%	8.82%	11.07%	15.30%	9.09%	1.33%	11.36%	12.07%	10.40%
Return on Equity (ROE)	0.87%	-21.28%	16.79%	20.93%	28.38%	18.16%	3.88%	23.48%	25.90%	24.03%
Cash Return on Invested Capital (CROIC)	25.07%	16.69%	13.49%	7.33%	1.13%	11.61%	13.13%	14.82%	9.27%	19.62%
Operating Return on Assets (OROA)	0.67%	-8.65%	4.74%	5.43%	6.18%	4.49%	2.46%	6.75%	8.37%	5.89%
Return on Assets (ROA)	-0.65%	-7.83%	2.55%	3.66%	5.31%	3.21%	-0.56%	5.69%	6.94%	6.11%
Return on Common Equity (ROCE)	0.87%	-21.28%	16.79%	20.93%	28.38%	18.16%	3.88%	23.48%	25.90%	24.03%
Return on Equity Simple (ROE_SIMPLE)	-0.68%	0.00%	-4.69%	-2.45%	2.29%	0.00%	8.95%	10.50%	11.10%	0.00%
Net Operating Profit after Tax (NOPAT)	17	-184	161	205	254	188	46	244	279	274
NOPAT Margin	1.84%	-18.97%	18.05%	21.36%	26.14%	18.62%	5.14%	23.81%	26.45%	25.15%
Net Nonoperating Expense Percent (NNEP)	0.71%	1.10%	1.84%	2.09%	2.40%	2.11%	1.45%	1.86%	1.68%	2.30%
Return On Investment Capital (ROIC_SIMPLE)	-	-2.09%	-	-	-	1.99%	-	-	-	2.68%
Cost of Revenue to Revenue	14.21%	17.22%	14.41%	10.19%	10.51%	10.60%	10.59%	10.73%	10.58%	11.83%
SG&A Expenses to Revenue	38.11%	39.42%	33.37%	35.60%	31.71%	39.14%	38.99%	33.06%	30.88%	33.94%
R&D to Revenue	15.83%	56.33%	21.33%	21.86%	24.11%	23.18%	25.82%	21.56%	18.95%	22.10%
Operating Expenses to Revenue	83.16%	109.88%	71.47%	73.35%	71.76%	77.30%	82.07%	69.79%	64.76%	70.64%
Earnings before Interest and Taxes (EBIT)	20	-266	129	155	171	132	65	200	260	184
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	169	-121	287	315	334	291	228	363	425	353
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.04	3.25	2.78	2.25	2.34	2.07	2.05	1.79	1.65	1.82
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.33	2.74	2.48	2.11	2.15	2.02	1.97	1.72	1.72	1.83
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	102.21	18.67	22.92	17.04	14.85	13.29
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.98%	5.36%	4.36%	5.87%	6.73%	7.52%
Enterprise Value to Invested Capital (EV/IC)	1.74	1.88	1.75	1.56	1.62	1.51	1.51	1.40	1.35	1.47
Enterprise Value to Revenue (EV/Rev)	3.68	4.06	3.70	3.27	3.24	3.09	2.99	2.67	2.60	2.60
Enterprise Value to EBITDA (EV/EBITDA)	15.07	27.30	24.04	18.93	15.12	9.65	9.83	8.60	7.94	7.72
Enterprise Value to EBIT (EV/EBIT)	58.56	0.00	0.00	317.18	64.87	20.14	21.95	18.43	15.82	14.91
Enterprise Value to NOPAT (EV/NOPAT)	76.17	0.00	0.00	389.57	91.20	14.58	15.97	13.98	13.71	12.34
Enterprise Value to Operating Cash Flow (EV/OCF)	11.90	11.69	9.99	8.92	9.71	10.83	11.05	9.74	8.91	7.57
Enterprise Value to Free Cash Flow (EV/FCFF)	6.15	10.28	12.11	20.54	143.35	12.95	11.30	9.19	14.65	7.17
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.09	1.86	1.72	1.62	1.64	1.53	1.54	1.52	1.47	1.49
Long-Term Debt to Equity	2.07	1.85	1.71	1.61	1.46	1.37	1.38	1.36	1.46	1.48
Financial Leverage	1.56	1.46	1.44	1.43	1.43	1.31	1.20	1.11	0.99	0.92
Leverage Ratio	3.42	3.28	3.29	3.34	3.46	3.26	3.18	3.10	3.06	2.99
Compound Leverage Factor	-10.23	4.20	1.40	1.76	2.02	1.52	-0.08	2.14	2.37	2.16
Debt to Total Capital	67.60%	64.97%	63.17%	61.86%	62.09%	60.45%	60.71%	60.27%	59.44%	59.87%
Short-Term Debt to Total Capital	0.37%	0.35%	0.34%	0.34%	6.57%	6.40%	6.44%	6.40%	0.30%	0.30%
Long-Term Debt to Total Capital	67.23%	64.62%	62.83%	61.52%	55.52%	54.05%	54.27%	53.87%	59.14%	59.57%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	32.40%	35.03%	36.83%	38.14%	37.91%	39.55%	39.30%	39.73%	40.56%	40.13%
Debt to EBITDA	6.55	10.50	9.95	8.81	7.02	4.66	4.89	4.70	4.68	4.46
Net Debt to EBITDA	5.52	8.89	7.92	6.71	5.07	3.33	3.33	3.07	2.67	2.28
Long-Term Debt to EBITDA	6.51	10.45	9.90	8.76	6.28	4.17	4.37	4.20	4.65	4.44
Debt to NOPAT	33.09	-124.80	-302.43	181.24	42.37	7.04	7.95	7.63	8.08	7.14
Net Debt to NOPAT	27.89	-105.58	-240.69	138.06	30.61	5.04	5.42	4.98	4.62	3.64
Long-Term Debt to NOPAT	32.91	-124.12	-300.80	180.26	37.89	6.29	7.10	6.82	8.04	7.10
Altman Z-Score	1.34	1.31	1.40	1.32	1.31	1.29	1.27	1.27	1.34	1.44
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.16	2.79	3.06	3.18	2.06	2.24	2.27	2.37	4.26	4.46
Quick Ratio	1.85	1.64	1.97	2.09	1.41	1.52	1.62	1.72	3.24	3.57
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1,987	1,308	1,321	771	205	291	343	634	230	891
Operating Cash Flow to CapEx	0.00%	3,646.52%	8,391.10%	5,171.02%	7,145.73%	1,656.49%	3,870.64%	4,672.85%	3,696.21%	2,999.77%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.31	0.32	0.33	0.34	0.35	0.35	0.34	0.35	0.34	0.35
Accounts Receivable Turnover	6.52	6.02	6.25	6.25	6.17	5.65	5.78	5.98	5.91	5.72
Inventory Turnover	0.55	0.61	0.67	0.69	0.74	0.66	0.64	0.69	0.74	0.83
Fixed Asset Turnover	0.00	15.09	15.41	16.05	17.29	19.28	19.52	19.62	20.02	23.72
Accounts Payable Turnover	6.13	5.66	5.57	6.11	4.67	4.50	3.90	4.24	4.35	4.94
Days Sales Outstanding (DSO)	56.02	60.59	58.40	58.41	59.11	64.60	63.20	61.07	61.77	63.80
Days Inventory Outstanding (DIO)	668.62	603.29	547.04	525.80	493.31	549.33	567.83	527.88	495.19	441.18
Days Payable Outstanding (DPO)	59.51	64.51	65.50	59.74	78.09	81.08	93.62	86.03	84.00	73.96
Cash Conversion Cycle (CCC)	665.14	599.37	539.94	524.47	474.33	532.86	537.42	502.93	472.96	431.03
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	7,563	7,919	7,879	7,873	7,612	7,817	7,583	7,483	7,660	7,200
Invested Capital Turnover	0.42	0.42	0.44	0.46	0.50	0.49	0.50	0.51	0.52	0.54
Increase / (Decrease) in Invested Capital	-1,970	-1,492	-1,160	-567	49	-102	-296	-390	49	-617
Enterprise Value (EV)	13,182	14,874	13,820	12,290	12,302	11,830	11,473	10,454	10,374	10,561
Market Capitalization	8,355	10,031	9,267	7,935	8,172	7,744	7,581	6,728	6,880	7,445
Book Value per Share	$43.80	$49.01	$52.66	$55.08	$55.27	$59.36	$59.11	$59.69	$67.54	$67.72
Tangible Book Value per Share	($70.48)	($69.90)	($65.57)	($61.29)	($57.56)	($54.55)	($52.43)	($48.43)	($44.98)	($39.34)
Total Capital	8,472	8,810	9,056	9,243	9,205	9,450	9,407	9,469	10,283	10,202
Total Debt	5,727	5,724	5,721	5,718	5,715	5,713	5,710	5,707	6,112	6,109
Total Long-Term Debt	5,696	5,693	5,690	5,687	5,111	5,108	5,105	5,101	6,081	6,078
Net Debt	4,827	4,843	4,553	4,355	4,130	4,087	3,892	3,726	3,494	3,116
Capital Expenditures (CapEx)	-4.90	9.38	3.82	5.74	4.30	10	6.90	7.09	11	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	890	822	739	733	691	877	765	751	773	629
Debt-free Net Working Capital (DFNWC)	1,790	1,704	1,907	2,096	2,277	2,504	2,583	2,731	3,391	3,621
Net Working Capital (NWC)	1,759	1,673	1,876	2,065	1,672	1,899	1,978	2,126	3,360	3,590
Net Nonoperating Expense (NNE)	37	56	92	100	107	94	61	75	64	83
Net Nonoperating Obligations (NNO)	4,818	4,834	4,544	4,347	4,122	4,080	3,886	3,720	3,489	3,106
Total Depreciation and Amortization (D&A)	149	145	157	160	163	159	163	163	165	168
Debt-free, Cash-free Net Working Capital to Revenue	24.84%	22.48%	19.76%	19.49%	18.22%	22.88%	19.90%	19.20%	19.37%	15.45%
Debt-free Net Working Capital to Revenue	49.93%	46.56%	51.00%	55.69%	60.01%	65.30%	67.21%	69.86%	84.94%	89.00%
Net Working Capital to Revenue	49.07%	45.72%	50.17%	54.87%	44.08%	49.52%	51.46%	54.37%	84.16%	88.24%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.31)	($3.86)	$1.09	$1.63	$2.33	$1.50	($0.23)	$2.68	$3.50	$3.11
Adjusted Weighted Average Basic Shares Outstanding	62.79M	62.54M	63.49M	63.99M	63.11M	63.29M	62.54M	62.88M	61.41M	61.84M
Adjusted Diluted Earnings per Share	($0.31)	($3.85)	$1.04	$1.52	$2.14	$1.40	($0.23)	$2.49	$3.42	$2.97
Adjusted Weighted Average Diluted Shares Outstanding	62.79M	62.54M	73.77M	73.54M	71.29M	72.07M	62.54M	69.63M	63.17M	66.01M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	62.97M	63.33M	64.00M	63.13M	62.96M	62.35M	63.04M	61.75M	60.45M	60.73M
Normalized Net Operating Profit after Tax (NOPAT)	111	-184	88	110	121	86	46	140	182	134
Normalized NOPAT Margin	11.79%	-18.97%	9.88%	11.53%	12.41%	8.47%	5.14%	13.64%	17.27%	12.27%
Pre Tax Income Margin	-6.39%	-34.97%	6.17%	8.54%	10.24%	6.08%	-0.18%	13.47%	19.03%	12.24%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.29%	-0.02%	0.00%	-110.50%	212.58%	65.03%	0.00%	84.98%	88.79%	55.60%

Frequently Asked Questions About Jazz Pharmaceuticals' Financials

When does Jazz Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Jazz Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Jazz Pharmaceuticals' net income changed over the last 9 years?

Jazz Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $560.12 million in 2024, rising from $329.53 million in 2015. The previous period was $414.83 million in 2023.

What is Jazz Pharmaceuticals's operating income?

Jazz Pharmaceuticals's total operating income in 2024 was $716.63 million, based on the following breakdown:

Total Gross Profit: $3.62 billion
Total Operating Expenses: $2.91 billion

How has Jazz Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Jazz Pharmaceuticals' total revenue changed from $1.32 billion in 2015 to $4.07 billion in 2024, a change of 207.1%.

How much debt does Jazz Pharmaceuticals have?

Jazz Pharmaceuticals' total liabilities were at $7.92 billion at the end of 2024, a 3.4% increase from 2023, and a 356.7% increase since 2015.

How much cash does Jazz Pharmaceuticals have?

In the past 9 years, Jazz Pharmaceuticals' cash and equivalents has ranged from $309.62 million in 2018 to $2.41 billion in 2024, and is currently $2.41 billion as of their latest financial filing in 2024.

How has Jazz Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Jazz Pharmaceuticals' book value per share changed from 26.00 in 2015 to 67.72 in 2024, a change of 160.5%.

Remove Ads

Related Companies

This page (NASDAQ:JAZZ) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jazz Pharmaceuticals (JAZZ) Financials

Frequently Asked Questions About Jazz Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jazz Pharmaceuticals (JAZZ) Financials

Annual Income Statements for Jazz Pharmaceuticals

Quarterly Income Statements for Jazz Pharmaceuticals

Annual Cash Flow Statements for Jazz Pharmaceuticals

Quarterly Cash Flow Statements for Jazz Pharmaceuticals

Annual Balance Sheets for Jazz Pharmaceuticals

Quarterly Balance Sheets for Jazz Pharmaceuticals

Annual Metrics and Ratios for Jazz Pharmaceuticals

Quarterly Metrics and Ratios for Jazz Pharmaceuticals

Frequently Asked Questions About Jazz Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools